#$mnkd

body { color: #4a4a4a; } body a { color: #1B86CE; text-decoration: none; } p { margin: 0; padding: 0; } table[class="wrapper"] { width:100% !important; table-layout: fixed; -webkit-font-smoothing: antialiased; -webkit-text-size-adjust: 100%; -moz-text-size-adjust: 100%; -ms-text-size-adjust: 100%; } img[class="max-width"] { max-width: 100% !important; } @media screen and (max-width:480px) { .preheader .rightColumnContent, .footer .rightColumnContent { text-align: left !important; } .preheader .rightColumnContent div, .preheader .rightColumnContent span, .footer .rightColumnContent div, .footer .rightColumnContent span { text-align: left !important; } .preheader .rightColumnContent, .preheader .leftColumnContent { font-size: 80% !important; padding: 5px 0; } table[class="wrapper-mobile"] { width: 100% !important; table-layout: fixed; } img[class="max-width"] { height: auto !important; } a[class="bulletproof-button"] { display: block !important; width: auto !important; font-size: 80%; padding-left: 0 !important; padding-right: 0 !important; } // 2 columns #templateColumns{ width:100% !important; } .templateColumnContainer{ display:block !important; width:100% !important; padding-left: 0 !important; padding-right: 0 !important; } } body, p, div { font-family: helvetica,arial,sans-serif; } body, p, div { font-size: 14px; }

Stocks with the highest positive earnings drift: MXPT, VVUS, SSYS, KRO, CMTL, RUBI, CECE, AMOT, NWPX, TSL.

 YOUR WEEKLY EDITION OF THE Top 10 Long/Short Estimize Signal Scores Monday, March 13, 2017

The Estimize Signal has identified the following 20 stocks to have the highest likelihood of positive and negative drift around their earnings today. The Signal is calculated by consolidating several predictive factors within Estimize’s earnings estimates collected from 45,000 buy side, independent, and amateur analysts.

Want premium access to this data everyday for use in trading? Email us at [email protected] »

At Estimize, we've always done extensive research on our crowdsourced earnings estimates. Every week, we'll be sharing some of our findings to help you effectively leverage Estimize's more accurate and representative earnings estimates. Please get in touch with us at [email protected] to discuss.

Top 10 Positive Signal Scores

Highlest likelihood of a positive pre/post earnings drift

1 MXPT MaxPoint Interactive Wed, Mar 8 99.73 post 2 VVUS Vivus Wed, Mar 8 99.73 post 3 SSYS Stratasys Thu, Mar 9 95.87 post 4 KRO Kronos Worldwide Fri, Mar 10 95.23 post 5 CMTL Comtech Telecomm. Wed, Mar 8 92.53 post 6 RUBI The Rubicon Project Tue, Mar 14 84.81 pre 7 CECE CECO Environmental Thu, Mar 9 79.09 post 8 AMOT Allied Motion Technologies Tue, Mar 14 71.40 pre 9 NWPX Northwest Pipe Company Wed, Mar 8 68.82 post 10 TSL Trina Solar Limited Mon, Mar 20 67.23 pre

Bottom 10 Negative Signal Scores

Highlest likelihood of a negative pre/post earnings drift

1 FNHC Federated National Holding Co Thu, Mar 9 -99.73 post 2 HZN Horizon Global Corp Thu, Mar 9 -99.46 post 3 GTT GTT Communications Wed, Mar 8 -99.46 post 4 RMTI Rockwell Medical Tue, Mar 21 -96.52 pre 5 ACTG Acacia Research Thu, Mar 9 -94.32 post 6 KEYW KEYW Holding Wed, Mar 8 -93.91 post 7 SCVL Shoe Carnival Thu, Mar 23 -89.85 pre 8 REIS Reis Inc Thu, Mar 9 -89.63 post 9 MNKD MannKind Thu, Mar 16 -85.86 pre 10 ENT Global Eagle Entertainment Mon, Mar 20 -84.10 pre

We've tested the Signal's predictive power as a stock selection signal in isolation over the last 5 years and it produced 23.1% returns and 1.75 sharpe. The Signal is best utilized in a dollar neutral portfolio consisting of the top and bottom decile of scores rebalanced daily at the open using a new score delivered via email or FTP/API. Want to get set up with premium access? Email us »

Email us at [email protected] to get premium access to this data.

EMAIL US

Join the world's top hedge funds using Estimize data to generate alpha

Estimize gives you access to the true market expectations on over 2,000 stocks, with earnings estimates that are more accurate than Wall Street 74% of the time. Crowdsourced from 45,000 regular contributors across the buy and sell-side, private investors, subject matter experts and academics, Estimize's data set is the next evolution of financial data. More inclusive, more accurate, and more representative, Estimize provides raw estimate data, factor models, visualization and screening tools to both fully systematic and discretionary institutional managers to help them generate alpha and manage risk. Learn how we can help you  »

DISCRETIONARY INVESTORS

QUANTITATIVE INVESTORS

Have something to say? Tweet us @Estimize

ESTIMIZE BLOG

EARNINGS CALENDAR

INSTITUTIONAL PRODUCTS

CONTACT US

New Post has been published on http://freetraderchat.com/blog/penny-stock-watch-list-2-1-2016/

Penny Stock Watch List – 2-1-2016 – $SFXE, $PGH, $UNIS, $ANAD, $MNKD

$SFXE

$PGH

$UNIS

$ANAD

New Post has been published on http://freetraderchat.com/blog/penny-stock-watch-list-1-27-2016-kgji-nxtd-aciiq-unis-gbsn/

Penny Stock Watch List – 1-27-2016 – $MNKD, $REXX, $ZINC, $NXTD, $UNIS

$MNKD

$REXX

$ZINC

$NXTD

New Post has been published on http://freetraderchat.com/blog/live-day-trade-jan-21-mnkd/

Live Day Trade – Jan 21 – $MNKD

These aren’t the type of stories that people like to hear about it. Most of you only want to see the wins. Its only right to show the losses as its apart of the game. I still think that losing sucks, but it doesn’t effect me like it used to.

I’m learning to become more self-conscious and aware of my thoughts after a loss. Its much easier to cope as time goes on. I broke my of my biggest rules today and paid the price.

Last Tuesday I traded $AEZS in the pre-market and won. That I assume gave me the confidence to go in on $MNKD this morning before the open. Stupid move. $AEZS had FDA news. $MNKD did not!

Fundamentals     

##Symbol##ENTA ##***Biotech ##Date##24 Aug 2015 I want to introduce you to a small biotech ($760 million market cap) that may be on the verge of a large break out. It doesn't get much fanfare, nor are its products known to the consumer, but it has its hands inside the guts of a potential blockbuster drug. Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. ENTA has a clever business model, cash on hand, and one big success already called protease inhibitor paritaprevir. That product goes into AbbVie's ground breaking hepatitis C treatment known as Viekira Pak (Source: The Motley Fool). The product is taking off and ENTA gets a 3% royalty fee from it, while carrying none of the large risks associated with a launching, marketing and selling and new drug. There is a non-trivial chance that this drug becomes a blockbuster hit and that means massive margins for ENTA. Let us not forget the success the Gilead had with its Hep C drug, Sovaldi, and $10 billion in revenue in its first year (the largest new drug success ever). According to WHO, there are over 180 million people worldwide with Hep C, and 3 million in the US. Yes, the blockbuster drug in this area was created by Gilead (GILD), but competition is coming. ENTA has seen revenue (TTM) rise over both one- and two-years by 221% and 358%, respectively. Revenue in the most recent trailing-twelve-months is $149 million. Last year ENTA reported $46 million and two-years ago annual revenue was $33 million. It has over $223 million in cash and equivalents and carries zero debt. It spends less than $20 million a year in R&D, which gives it future product capacity at a low cost. Further, the company went from less than ~$2.85 million in levered free cash flow a year ago, to now over $76.5 million in the trailing-twelve-months, which yields the ridiculous 2,600% year-over-year comparison.

Love Biotech? Join us in the Biotech Corner ➣ http://t.co/uge1yqEXIZ pic.twitter.com/sAeKDgtpLK

— Ophir Gottlieb (@OphirGottlieb) August 28, 2015

➜ ENTA has 1 products in Phase II trials and 4 products in the Phase III trials. Everything about the company's fundamentals can change in a single day when the FDA makes a definitive decision on a late stage drug trial. ➜ ENTA generates $1.17 in revenue for every $1 in expense, which is very high and considerably above the sector average of $0.70 and remarkable for a small biotech. ➜ ENTA generates $918,000 in revenue per employee which is above the sector average of $589,000.

Technicals   |   Support: 38.92   |   Resistance: 42.03   

Swing Death Cross Alert: The short-term 10 day MA is now below the 50 day MA. ENTA is hitting a technical breakdown right now. The stock has a one bull (lowest rated) technical rating because while it's trading above its 10-day moving average, it's down on e the day, trading below both the 50- and 200-day moving averages and the 10 day MA is below the 50 day MA ("swing death cross"). I remind all readers that a report just like this one is available for any company for free on CMLviz.com. No e-mail. No login. Free. Forever. Period. Let's quickly look at the core elements that drive the company's fundamental rating.

Fundamentals Rating Summary

Stock Returns and Chart

ENTA is up +1.2% over the last three months and up +14.5% over the last six months. The stock has returned -6.5% over the last year. Before we dig into the fundamental trends that drive the rating, let's look at an all-time stock chart with regression channel and 10-day momentum (on the bottom). Click here to interact with this stock chart Now let's examine the visualizations of the critical financial measures.

METRIC CURRENT 1YR AGO 2YR AGO DIRECTION Revenue (TTM US$ Millions) 1494633RISING

ENTA is not only growing revenue by 221.0% year-over-year, but it's 4 fundamental (star) rating implies that the revenue acceleration is pushing the core fundamentals of the company forward. While massive revenue growth often times comes at the expense of earnings, free cash flow and operating margins, that is not at all the case for ENTA. This is how little boitechs turn into monsters, and while ENTA doesn't quite have the business model to turn into a true mega cap, it does have a big winner on its hands, and that means more money to try to repeat the success. What do all these numbers mean? ENTA's fundamental rating benefited these results: 1. The one-year change was positive. 2. The one-year change was greater than +20% (an extra boost to the rating). 3. The two-year change was positive. Let's look at Revenue (TTM US$ Millions) in the chart below. Click Here to Interact With This Chart Click Here for a Head-to-Head Trade Card on Any Companies

METRIC CURRENT 1YR AGO 2YR AGO DIRECTION Net Income (TTM US$ Millions) 683510RISING

Net Income (after tax profit) over the trailing twelve months (TTM) for ENTA is rising, up 95% year-over-year. That net income number could multiply several fold if Hep C drug Viekira Pak really does prove to be a monster. In our next chart we plot Net Income (TTM US$ Millions) in the blue bars. Click Here to Interact With This Chart

METRIC CURRENT 1YR AGO 2YR AGO DIRECTION Research and Development (US$ Millions) 654RISING

Research and Development (US$ Millions) in the most recent quarter for ENTA was $6 million, up 37% year-over year. Further, we can see that R&D today relative to two-years ago is up 55% from $4 million. While those R&D comps sound like spending gone wild, in absolute numbers it's quite controlled and methodical. In our final time series chart we plot Research and Development (US$ Millions) in the blue bars. Note that the green bar represents the all-time high. Click Here to Interact With This Chart

Love Biotech? Join us in the Biotech Corner ➣ http://t.co/uge1yqEXIZ pic.twitter.com/sAeKDgtpLK

— Ophir Gottlieb (@OphirGottlieb) August 28, 2015

Today we’re joined by Joe McCann, a former biotech analyst at CR Intrinsic and the CEO of Slingshot Insights. In this episode Joe discusses Biogen’s (BIIB) new drug which could be the holy grail for biotech stocks, Leigh and Joe chat about a hedge fund which seeks to make drug prices cheaper, and they wrap things up with a complete earnings overview for the biotech sector.